Monoclonal Antibodies + Efgartigimod Alfa Interaction
Moderateinteraction on record
Description
Concomitant use may lower systemic exposures and reduce effectiveness of monoclonal antibodies. Closely monitor for reduced effectiveness.
Mechanism
VYVGART binds to human neonatal Fc receptor (FcRn), which may lower systemic exposures of FcRn-binding medications
Source: NLP:efgartigimod alfa